A Multicenter Randomized Controlled Trial of a Liquid Loperamide Product Versus Placebo in the Treatment of Acute Diarrhea in Children

Abstract

This randomized, double-blind, placebo-controlled trial of 48 hours' duration conducted in 13 primary care ambulatory practices in the United States and Mexico was used to compare the efficacy and safety of loperamide with placebo for the treatment of acute diarrhea in children aged 2 through 11 years. Two hundred fifty-eight children with acute nonspecific diarrhea were enrolled. Children were randomly assigned to treatment with loperamide HCO 0.5 mg/5 mL (n= 130) or placebo (n=1 28). The first dose of loperamide consisted of either 1.0 mg (children 2 through 5 years of age) or 2.0 mg (children 6 through 11 years of age) of study medication under the observation of study personnel. This was followed by 1 mg after each unformed stool, with a total daily dose of up to 3.0 mg in the children 2-5 years of age, 4.0 mg in the children 6-8 years of age, and 6.0 mg in the children 9-11 years of age. The primary outcome measures were time to last unformed stool, time to first unformed stool, number of unformed stools during six consecutive 8-hour periods, and overall rating of efficacy/acceptability. Secondary outcomes included abdominal pain/cramping, vomiting, and fever. Children who received loperamide had significantly shorter time to last unformed stool (p=0.001⁷) and fewer numbers of unformed stools (p=0.0237) than children who received placebo. The end-of-study overall efficacy/acceptability rating of loperamide was significantly better than for placebo (p=0.010⁷). All other clinically important outcome measures related to diarrhea relief favored loperamide. There was no significant difference in the incidence of drug-related adverse events between treatment groups, although total adverse events were reported more frequently (p=O.048) by the loperamide group (15%) compared with the placebo group (7%). In conclusion, this controlled study provides data demonstrating that at recommend doses, loperamide is well tolerated and significantly shortens the duration and severity of symptoms of acute nonspecific diarrhea in children 2 through 11 years of age.

Get full access to this article

View all access options for this article.

References

1. Glass RI , Lewj F , Gangarosa RE , et al. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr. 1991;118:S27-S33.

2. National ambulatory medical care survey . In: Facts About Family Practice. Kansas City, MO: American Academy of Family Physicians; 1996:54-55.

3. Guerrant RL , Bobak DA . Bacterial and protozoal gastroenteritis. NEngl J Med. 1991;325:327-340.

4. Blacklow NR , Greenberg HB . Viral gastroenteritis. N Engl J Med. 1991; 325:252-264.

5. Gastanaduy AS , Begue RE . Acute gastroenteritis. Clin Pediatr. 1999;38:1-12.

6. World Health Organization . The rational use of drugs in the management of acute diarrhoea in children. Geneva: World Health Organization; 1990.

7. Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis . Practice parameter: the management of acute gastroenteritis in young children. Pediatrics. 1996;97:424-433.

8. Haak H , Claeson ME . Regulatory actions to enhance appropriate drug use: the case of antidiarrhoeal drugs. Soc Sci Med. 1996;42:1011-1019.

9. Anderson J . Double-blind comparison of loperamide HCl and placebo in the treatment of acute diarrhea in children. Advances in Therapy. 1984;1:14-18.

10.

10. Diarrhoeal Diseases Study Group (UK) . Loperamide in acute diarrhoea in childhood: results of a double blind, placebo-controlled multicenter clinical trial. Br Med j. 1984;289:1263-1267.

11.

11. Karrar ZA , Abdulla MA , Moody JB , et al. Loperamide in acute diarrhoea in childhood: results of a double blind, placebo-controlled clinical trial. Ann Trop Paediatr. 1987;7:122-127.

12.

12. Dukes GE . Over-the-counter antidiarrheal medications used for the selftreatment of acute nonspecific diarrhea. Am J Med. 1990;88(suppl 6A):24S-26S.

13.

13. Prakash P , Saxena S , Sareen DK Loperamide versus diphenoxylate in diarrhea of infants and children. Indian J Pediatr. 1980;47:303-306.

14.

14. McNeil Consumer Healthcare IMODIUM® A-D (loperamide hydrochloride) . In: Physicians' Desk Reference, 53rd ed., Montvale NJ: Medical Economics Company; 1999:1671-1671.

15.

15. Caeiro JP , Mathewsonj , Smith MA , et al. Etiology of outpatient pediatric nondysenteric diarrhea: a multicenter study in the United States. Pediatr Infect Dis J 1999;18:94-97.

16.

16. Collett D. Modelling Survival Data in Medical Research. London, England: Chapman & Hall; 1994.

17.

17. Pocock Sj . Clinical Trials: a Practical Approach. Chichester, England: Wiley & Sons; 1983.

18.

18. Cleason M , Merson MH . Global progress in the control of diarrheal diseases. Pediatr Infect Disj. 1990;9:345-355.

19.

19. Motola C , Hill ID , Mann MD , Bowie MD . Effect of loperamide on stool output and duration of acute infectious diarrhea in infants. J Pediatr. 1990;1 17:467-471.

20.

20. Owens JR , Broadhead R , Hendrickse RG , et al. Loperamide in the treatment of acute gastroenteritis in early childhood. Report of a two centre, double-blind, controlled clinical trial. Ann Trop Paediatr. 1981;1:135-141.

21.

21. Kassem AS , Madkour AA , Massoud BZ , Mehanna ZM . Loperamide in acute childhood diarrhoea: a double blind controlled trial. J Diar Dis Res. 1983;1:10-16.

22.

22. Chow CB , Li SH , Leung NK . Loperamide associated necrotising enterocolitis. Acta Poadiatr Scand. 1986; 75:1034-1036.

23.

23. Bhutta TI , Tahir KI . Loperamide poisoning in children. Lancet. 1990; 335-363.

24.

24. Herranz J , Luzuriaga C , Sarralle R , Florez J . Sintomas neurologicos secundarios al tratamiento con loperamida en la infancia. Anal Espanoe Pediatr. 1980;13:pp not given.

25.

25. Litovitz T , Clancy C , Korberly B , et al. Surveillance of loperamide ingestions: an analysis of 216 poison center reports. Clin Toxicol. 1997;35:11-19.